The Binding Site

The Binding Site The Specialist Protein Company

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation. Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders. Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years. We are committed to working in collaboration with our partners and customers to lead the way in specialized medical diagnostics, ensuring we continue to make a difference together.

Accurate disease monitoring depends on more than detection alone – it requires reliable quantification.In our latest cli...
03/04/2026

Accurate disease monitoring depends on more than detection alone – it requires reliable quantification.

In our latest clinical case study and podcast, we discuss how conventional methods such as SPE and IFE can struggle to reliably detect and quantify M-proteins when IgA M-proteins co-migrate in the beta region.

Visit the webpage here: http://spr.ly/6184B6oYbE to listen to the podcast, and download this latest case study where we discuss this in more detail

Lab Week 2026 is happening April 19-25. This year’s theme is “Lab Story: To Infinity and Beyond for Our Patients!” To us...
02/04/2026

Lab Week 2026 is happening April 19-25. This year’s theme is “Lab Story: To Infinity and Beyond for Our Patients!” To us, that means monoclonal protein testing for early detection of multiple myeloma, and so, we’re excited to offer multiple P.A.C.E.®-approved presentations on the subject:

LIVE: Monoclonal Protein Testing Clinical Utility, Challenges & Opportunities (45-minute program, .5-hour credit/ Intermediate)

Tuesday, April 21st
▪️ 10:00 am PT/1:00 pm ET, Kasey Yagnik, PhD, Medical Science Liaison: https://event.eu.on24.com/wcc/r/8000195052/32BDBE37019613E8E661F78F212644C9?partnerref=facebook
▪️ 12:00 pm PT/3:00 pm ET, Stephanie Brunelle, Medical Science Liaison: https://event.eu.on24.com/wcc/r/8000194847/030E8E2EF9068B8F55032BB9A0848338?partnerref=facebook

Thursday, April 23rd
▪️ 9:00 am PT/12:00 pm ET, Kasey Yagnik, PhD, Medical Science Liaison: https://event.eu.on24.com/wcc/r/8000195060/6D29A04AA6D7B8B3A76E6D9C48B2F07C?partnerref=facebook
▪️ 11:00 am PT/2:00 pm ET, Stephanie Brunelle, Medical Science Liaison: https://event.eu.on24.com/wcc/r/8000194849/563536ECBC2B53486A08F1A81AD0ED8A?partnerref=facebook

SELF-STUDY: Monoclonal Protein Testing Clinical Utility, Challenges & Opportunities, (45-minute program, .5 credits/ Intermediate)
▪️ Presented by Bhrugu Yagnik, MS, PhD, BC-MSLcertTM: https://event.eu.on24.com/wcc/r/8000186824/F340BAE1E90B2A8D4FC5CF9767F9D6B6?partnerref=facebook

In the era of modern therapeutics, is immunofixation still sensitive enough to monitor treatment response in Multiple My...
01/04/2026

In the era of modern therapeutics, is immunofixation still sensitive enough to monitor treatment response in Multiple Myeloma?

Clinical scientists in Spain have led a multicenter study showing that the EXENT® System detects low-level monoclonal protein more frequently and with greater clinical insight than immunofixation in Multiple Myeloma.

The research highlights how more sensitive methods may improve disease monitoring and response evaluation beyond traditional techniques.

Read the Scientific Short here: http://spr.ly/6185B6WbEP

This March, we learned, shared, and amplified facts about multiple myeloma, from symptoms and populations at higher risk...
31/03/2026

This March, we learned, shared, and amplified facts about multiple myeloma, from symptoms and populations at higher risk to health disparities and progress in survival.

Thank you to everyone who helped spread awareness and support the myeloma patient community.

Raising awareness is not a one-month effort. It’s an ongoing commitment. Let’s continue the conversation. Learn more about multiple myeloma and find resources at the International Myeloma Foundation here: http://spr.ly/6189hsjYv

Multiple Myeloma is one of the most common blood cancers, yet awareness remains limited. On March 26, iconic landmarks w...
30/03/2026

Multiple Myeloma is one of the most common blood cancers, yet awareness remains limited.

On March 26, iconic landmarks will glow red to shine a light on the impact of myeloma and the importance of continued education and advocacy. Let’s make myeloma visible. Explore resources and ways to take action here: http://spr.ly/6183hsjuh

Don’t miss our Multiple Myeloma Action Month webinar on addressing diagnostic delays. The webinar is available on demand...
30/03/2026

Don’t miss our Multiple Myeloma Action Month webinar on addressing diagnostic delays. The webinar is available on demand. Watch Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, share practical insights for primary care providers on improving early diagnosis and care coordination.

Key topics covered:

- Signs and symptoms of multiple myeloma and monoclonal gammopathies
- Challenges and consequences of delayed diagnosis
- Addressing healthcare disparities in multiple myeloma
- Enhancing confidence in test selection and interpretation

Watch the webinar: http://spr.ly/6182h4bjO

In 1990, the average life expectancy following a Multiple Myeloma diagnosis was approximately 2 to 3 years. Today, advan...
27/03/2026

In 1990, the average life expectancy following a Multiple Myeloma diagnosis was approximately 2 to 3 years.

Today, advances through research, earlier detection, and improved treatment options mean many patients are living 10 years or longer after diagnosis, with some living 20 or even 30+ years.

While myeloma remains an incurable disease, outcomes have improved significantly over the past three decades. Learn the facts and find useful information from the IMF here: http://spr.ly/6186hsj6Q

26/03/2026

Multiple myeloma is often overlooked, but early detection can change lives. Watch as Donna Catamero, NP, Associate Director at Mount Sinai Cancer Institute, discusses the critical steps in diagnosing multiple myeloma. Learn who is most at risk, key symptoms to recognize, how to test, and survival rates. This insightful video provides essential information for healthcare professionals and anyone looking to raise awareness.

Watch the video to learn how early detection can change lives: http://spr.ly/6183h4bKV

Although multiple myeloma represents a relatively small proportion of overall cancer diagnoses, it is one of the most co...
25/03/2026

Although multiple myeloma represents a relatively small proportion of overall cancer diagnoses, it is one of the most common blood cancers.

Each year, thousands of individuals and families begin facing the physical, emotional, and practical challenges of this disease.

Raising awareness helps improve understanding of symptoms, populations at higher risk and the importance of timely medical evaluation.

Learn more about Myeloma, including symptoms, risk factors, and the importance of early detection here: http://spr.ly/6189hsbIS

Myeloma doesn’t impact everyone equally. Black Americans face the highest risk of developing this disease. Greater awar...
23/03/2026

Myeloma doesn’t impact everyone equally.

Black Americans face the highest risk of developing this disease. Greater awareness of symptoms, populations at higher risk, and the impact of a timely medical evaluation can help support earlier diagnosis and more equitable care.

Learn more about the signs and how to support earlier diagnosis in higher risk populations: http://spr.ly/6180hsbmj

When serum protein electrophoresis (SPEP) is ordered alone, 1 in 8 patients with multiple myeloma may be missed. But ord...
23/03/2026

When serum protein electrophoresis (SPEP) is ordered alone, 1 in 8 patients with multiple myeloma may be missed. But ordering the complete panel of SPEP, immunofixation electrophoresis (IFE), and serum free light chain (sFLC) testing achieves greater than 99% diagnostic sensitivity. This Multiple Myeloma Action Month, turn awareness into action with comprehensive testing. The right tests at the right time can close the gap between symptoms and diagnosis. Action starts with ordering the full panel. The right tests at the right time can close the gap between symptoms and diagnosis.

Learn more: http://spr.ly/6184h4wQs

Early detection can make a meaningful difference in Multiple Myeloma. Symptoms such as fatigue, bone pain, or recurrent ...
20/03/2026

Early detection can make a meaningful difference in Multiple Myeloma.

Symptoms such as fatigue, bone pain, or recurrent infections can be non-specific or attributed to other causes, diagnosis is sometimes delayed. This makes myeloma one of the most common cancers to be diagnosed in accident and emergency rooms.

Raising awareness of the signs and encouraging timely medical evaluation can help support earlier diagnosis and access to care. Discover the key signs and how earlier recognition can support higher-risk populations. http://spr.ly/6181hsbzD

Address

8 Calthorpe Road, Edgbaston
Birmingham
B151QT

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 5pm

Telephone

+441214569500

Website

Alerts

Be the first to know and let us send you an email when The Binding Site posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to The Binding Site:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category